Literature DB >> 12424151

Bisphosphonates as adjuvant treatment for breast cancer.

Julie R Gralow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12424151      PMCID： PMC1124564          DOI： 10.1136/bmj.325.7372.1051

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

Authors:  L S Rosen; D Gordon; M Kaminski; A Howell; A Belch; J Mackey; J Apffelstaedt; M Hussein; R E Coleman; D J Reitsma; J J Seaman; B L Chen; Y Ambros
Journal:  Cancer J       Date:  2001 Sep-Oct       Impact factor: 3.360

2.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.

Authors:  T Saarto; C Blomqvist; P Virkkunen; I Elomaa
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

Review 3.  Bisphosphonates for breast cancer.

Authors:  N Pavlakis; M Stockler
Journal:  Cochrane Database Syst Rev       Date:  2002

4.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

Authors:  A Lipton; R L Theriault; G N Hortobagyi; J Simeone; R D Knight; K Mellars; D J Reitsma; M Heffernan; J J Seaman
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

5.  Palliative pamidronate treatment in patients with bone metastases from breast cancer.

Authors:  A T van Holten-Verzantvoort; H M Kroon; O L Bijvoet; F J Cleton; L V Beex; G Blijham; J Hermans; J P Neijt; S E Papapoulos; H P Sleeboom
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

6.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

Authors:  Trevor Powles; Sandy Paterson; John A Kanis; Eugene McCloskey; Sue Ashley; Alwynne Tidy; Kirsi Rosenqvist; Ian Smith; Lars Ottestad; Sandra Legault; Marjo Pajunen; Auli Nevantaus; Esa Männistö; Anne Suovuori; Sari Atula; Jaakko Nevalainen; Liisa Pylkkänen
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

Authors:  I J Diel; E F Solomayer; S D Costa; C Gollan; R Goerner; D Wallwiener; M Kaufmann; G Bastert
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

8.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

9.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

Authors:  A H Paterson; T J Powles; J A Kanis; E McCloskey; J Hanson; S Ashley
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544
  9 in total
  1 in total

Review 1.  Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer.

Authors:  Toni M Dando; Lynda R Wiseman
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.